减重药巨头在口服药上拼数据:礼来宣布自研GLP-1制剂降糖、减重效果优于口服司美格鲁肽

每日经济新闻
Sep 19, 2025

近日,礼来公司公布了在研口服小分子GLP-1 RA(胰高血糖素样肽‐1受体激动剂)药物“orforglipron”的Ⅲ期临床研究“ACHIEVE-3”的顶线结果。该结果显示,orforglipron的降糖效果显著优于口服司美格鲁肽。  《每日经济新闻》记者注意到,口服司美格鲁肽是全球首个获批的口服GLP-1 RA(胰高血糖素样肽-1受体激动剂)药物,也是全球首个针对减重适应证递交上市申请的口服...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10